Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial.

MLA

Muñoz-Rivas, Nuria, et al. “Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial.” Journal of Clinical Medicine, vol. 11, no. 19, Oct. 2022, p. 5632. EBSCOhost, https://doi.org/10.3390/jcm11195632.

APA

Muñoz-Rivas, N., Aibar, J., Gabara-Xancó, C., Trueba-Vicente, Á., Urbelz-Pérez, A., Gómez-Del Olmo, V., Demelo-Rodríguez, P., Rivera-Gallego, A., Bosch-Nicolau, P., Perez-Pinar, M., Rios-Prego, M., Madridano-Cobo, O., Ramos-Alonso, L., Alonso-Carrillo, J., Francisco-Albelsa, I., Martí-Saez, E., Maestre-Peiró, A., Méndez-Bailón, M., Hernández-Rivas, J. Á., & Torres-Macho, J. (2022). Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial. Journal of Clinical Medicine, 11(19), 5632. https://doi.org/10.3390/jcm11195632

Chicago

Muñoz-Rivas, Nuria, Jesús Aibar, Cristina Gabara-Xancó, Ángela Trueba-Vicente, Ana Urbelz-Pérez, Vicente Gómez-Del Olmo, Pablo Demelo-Rodríguez, et al. 2022. “Efficacy and Safety of Tinzaparin in Prophylactic, Intermediate and Therapeutic Doses in Non-Critically Ill Patients Hospitalized with COVID-19: The PROTHROMCOVID Randomized Controlled Trial.” Journal of Clinical Medicine 11 (19): 5632. doi:10.3390/jcm11195632.